Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Cytokinetics, IncorporatedNASDAQ: CYTK

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables growth accelerates

Q2 FY2026 accounts receivables of $17.61M (cash outflow) rose 175.2% year over year, ahead of the +90.5% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 1.3% of revenue in FY2025, down 81.9 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +175.2% holds above the trailing-twelve-month pace of +90.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$17.61M-261.0% QoQ
Last fiscal yearDec 2025
-$1.11M-92.8% YoY
LTMJun 2026
-$16.02M+90.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+175.2%——
1 year-92.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(1.11M) USD
Year-over-year change
+92.8%

Accounts Receivables vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 accounts receivables of $16.02M is the largest of the 3 companies compared; the peer median is $5.31M.
  • Accounts receivables amounts to 22.6% of revenue for CYTK, versus a peer median of 2361.6%.
CYTK Competitors Peer median
Accounts Receivables for CYTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$16.02M +90.5%—22.6%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$10.63M ——4723.1%
RNAAtrium Therapeutics, Inc.FY2025$0 ——0.0%
KARDKardigan, Inc.—— ———
Peer median (excluding CYTK) $5.31M——2361.6%

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
Deferred Income Tax2.84M0000
Stock-Based Compensation26.83M47.85M72.07M97.84M112.29M
Change in Working Capital8.46M(24.7M)3.09M35.66M(35.63M)
Accounts Receivables(47.4M)56.67M(1.14M)(15.37M)(1.11M)
Inventory00000
Accounts Payables1.06M4.52M(3.48M)(4.48M)2.66M
Other Working Capital54.8M(85.9M)7.71M55.51M(37.18M)
Other Non-Cash Items32.38M60.48M24.87M50.6M188.16M
Operating Cash Flow(142.52M)(299.52M)(414.33M)(395.89M)(510.01M)
Capital Expenditures(48.87M)(11.34M)(1.42M)(3.91M)(24.81M)
Acquisitions (Net)98.91M250.8M000
Purchases of Investments(525.04M)(855.39M)(635.21M)(1.29B)(1.06B)
Sales of Investments426.14M604.59M875.88M744.23M1.11B
Other Investing Activities(98.91M)(250.8M)00(5M)
Investing Cash Flow(147.78M)(262.13M)239.25M(553.1M)16.67M
Debt Repayment0334.66M(858K)(9.62M)490.95M
Common Stock Issued312.05M17.54M164.23M706.84M35.98M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.93M163.96M57.94M233.39M(2.47M)
Financing Cash Flow319.98M516.17M221.32M930.61M524.46M
Effect of Forex Changes00(20K)209K(715K)
Net Change in Cash29.68M(45.48M)46.22M(18.17M)30.4M
Free Cash Flow(191.39M)(310.85M)(415.75M)(399.8M)(534.82M)

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.